Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 171

Sort by

Sort Order Select

Journal Articles

Survival Patterns in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: Treatment Trajectories and Responses after the First Relapse

Ahmad S Halwani, MD, Hsu-Chih Chien, PhD MSc, Deborah Kay Morreall, BS, Vikas Patil, MS, Kelli M Rasmussen, MS, Catherine Li, PhD, Zachary R Burningham, PhD, Anthony S Masaquel, PhD MPH, Mary Halloran, PharmD, BCPS, Elisha Delong-Sieg, PharmD, Mathias Schulz, MD MBA, Jia Li, PhD, Brian C Sauer, PhD

Blood (2019) 134 (Supplement_1): 1622.

https://doi.org/10.1182/blood-2019-127719

Published: 2019

Journal Articles

TEM-MM-101: A Phase I/IIa Dose Escalation Study Evaluating the Safety and Activity of Autologous CD34+ Enriched Hematopoietic Progenitor Cells Genetically Modified for Human Interferon-α2 in Multiple Myeloma Patients with Early Relapse after Intensive Front Line Therapy

Bernhard Gentner, MD, Francesca Farina, MD, Matteo Giovanni Carrabba, MD, Magda Marcatti, MD, Stefania Girlanda, MD, Gabriele Antonarelli, MD, Capotondo Alessia, PhD, Stefania Mazzoleni, PhD, Carlo Russo, MD, Luigi Naldini, MD PhD, Fabio Ciceri, MD

Blood (2019) 134 (Supplement_1): 2064.

https://doi.org/10.1182/blood-2019-123749

Published: 2019

Journal Articles

Inpatient Hospitalization's Associated Cost and Mortality for Myeloma Patients Undergoing Autologous Stem Cell Transplant: A 13-Year Analysis of the National Inpatient Sample

Saqib Abbasi, MD, Brian McClune, DO, Leyla Shune, MD, Suman Kambhampati, MD, Saqib Abbasi, MD

Blood (2019) 134 (Supplement_1): 3431.

https://doi.org/10.1182/blood-2019-131622

Published: 2019

Journal Articles

Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming

Federico Simonetta, MD PhD, Toshihito Hirai, MD PhD, Juliane K. Lohmeyer, MD, Kristina Maas-Bauer, MD, Maite Alvarez, PhD, Arielle S. Wenokur, Jeanette Baker, Amin Aalipour, PhD, Samuel Haile, PhD, Crystal L. Mackall, MD, Robert S. Negrin, MD

Blood (2019) 134 (Supplement_1): 867.

https://doi.org/10.1182/blood-2019-122515

Published: 2019

Journal Articles

Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information

Anas Younes, MD, Grzegorz Nowakowski, MD, Allison C. Rosenthal, DO, Lori A. Leslie, MD, Han W. Tun, MD, Matthew A. Lunning, DO, FACP, Iris Isufi, MD, Robert Martell, MD PhD, Krish Patel, MD

Blood (2019) 134 (Supplement_1): 5327.

https://doi.org/10.1182/blood-2019-131851

Published: 2019

Journal Articles

Decreased Mortality after the First Year of Allogeneic Hematopoietic Stem Cell Transplant in Recipients of Umbilical Cord Blood Vs. Matched Related or Matched Unrelated Donors

Lauren M. Bohannon, BS, Kristin M. Page, MD, Yi Ren, MS, Sin-Ho Jung, PhD, Vinay K. Giri, BS, Meagan V. Lew, BS, Matthew Kelly, MD, Taewoong Choi, MD, Cristina Gasparetto, MD, Gwynn D. Long, MD, Richard D. Lopez, MD, David A. Rizzieri, MD, Stefanie Sarantopoulos, MD PhD, Nelson J. Chao, MD, Mitchell E. Horwitz, MD, Anthony D. Sung, MD

Blood (2019) 134 (Supplement_1): 4613.

https://doi.org/10.1182/blood-2019-126906

Published: 2019

Journal Articles

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study

Blood (2019) 134 (Supplement_1): 862.

https://doi.org/10.1182/blood-2019-126378

Published: 2019

Journal Articles

Whole Genome Sequencing Reveals Recurrent Structural Driver Events in Peripheral T-Cell Lymphomas Not Otherwise Specified

Francesco Maura, Niccolò Bolli, Daniel Leongamornlert, BS, Cristiana Carniti, Anna Dodero, MD, Federico Abascal, Adele Testi, Bernardo Rodriguez-Martin, Alessio Pellegrinelli, Giulia Biancon, Martina Magni, Annalisa Chiappella, MD, Inigo Martincorena, Jose M. C. Tubio, Giancarlo Pruneri, Peter J. Campbell, PhD, Paolo Corradini, MD

Blood (2018) 132 (Supplement 1): 4115.

https://doi.org/10.1182/blood-2018-99-112094

Published: 2018

Journal Articles

A New Cellular Immunotherapy for the Treatment of Multiple Myeloma without Development of Graft-Versus-Host Disease

Michael A Firer, PhD, Sofi Yado, BSc, MSc, Luboshits Galia, PhD, Reuven Or, MD

Blood (2018) 132 (Supplement 1): 3339.

https://doi.org/10.1182/blood-2018-99-110292

Published: 2018

Journal Articles

Fixed Dose Carfilzomib Triplets in Lenalidomide Refractory Myeloma

David Simpson, MBChB, FRACP, FRCPA, Henry Chan, MBChB

Blood (2018) 132 (Supplement 1): 3306.

https://doi.org/10.1182/blood-2018-99-110891

Published: 2018

Journal Articles

CD117-Amanitin Antibody Drug Conjugates Effectively Deplete Human and Non-Human Primate HSCs: Proof of Concept As a Targeted Strategy for Conditioning Patients for Bone Marrow Transplant

Bradley R Pearse, PhD, Sean M McDonough, MS, Jennifer L Proctor, BS, Rajiv Panwar, PhD, Ganapathy Sarma, PhD, Molly A McShea, MS, Lena Kien, BS, Junia Dushime, BS, Hillary L Adams, MS, Sharon L. Hyzy, MS, Melissa L. Brooks, BS, Rahul Palchaudhuri, PhD, Qing Li, PhD, Nathan M Kallen, BA, Pranoti Sawant, MS, Charlotte F McDonagh, PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD

Blood (2018) 132 (Supplement 1): 3314.

https://doi.org/10.1182/blood-2018-99-114881

Published: 2018

Journal Articles

Quadruple Hit Lymphoma: A Rare Entity with Dismal Prognosis

Jonathan Proulx, MD, Ryan Denley, DO, Bader Maria Pedemonte, MD, Ashish A. Shah, DO, Rachel Ochs, MD, Missak Haigentz, Jr., MD, Angela T. Alistar, MD, Ellen Early, MD, Eric D Whitman, MD, Mohamad Cherry, MD MS

Blood (2018) 132 (Supplement 1): 5305.

https://doi.org/10.1182/blood-2018-99-120147

Published: 2018

Journal Articles

Long Term Survival Analysis of Multiple Myeloma Patients Receiving Induction Therapy+ Autologous STEM CELL Trasplantation, Comparing Velcade-Dexametasone to Alkylating Polichemotherapy As Induction Therapy

Blood (2018) 132 (Supplement 1): 5764.

https://doi.org/10.1182/blood-2018-99-116924

Published: 2018

Journal Articles

Long Acting Zoledronic Acid Treatment for Vertebral Fracture Prevention in Multipl Myeloma Patients with Osteoporosis

Murat Cinarsoy, Ahmet Kursad Gunes, Hilmi Erdem Gozden

Blood (2018) 132 (Supplement 1): 1954.

https://doi.org/10.1182/blood-2018-99-111133

Published: 2018

Journal Articles

A Study to Identify Correlation of Hematopoietic Progenitor Cell(XN-HPC) By Sysmex Cell Counters with Final Yield of CD34 + Stem Cells

Kishore Kumar, MBBS, MD DM, Chezhian s Subash, FRCPath

Blood (2017) 130 (Supplement 1): 5458.

https://doi.org/10.1182/blood.V130.Suppl_1.5458.5458

Published: 2017

Journal Articles

Magic-TT Mediated Hematopoietic Stem/Progenitor Cells Promote Hematopoietic Recovery after Autologous Bone Marrow Transplantation

Yongjun Zhou, MD, Qiuxia Zhang, MD, Qiusui Mai, MD, Shan Jiang, Hao Huang, Linlin Zhang, MD, Xiaowei Sun, Minchun Zhang, Pengxin Qiao, Chun Zou, Xiaoli Chen, Zhihao Zheng, Jerry Kitbok Majaw, Qifa Liu, MD, Jing Sun, MD, Qianli Jiang, MD PhD

Blood (2017) 130 (Supplement 1): 4952.

https://doi.org/10.1182/blood.V130.Suppl_1.4952.4952

Published: 2017

Journal Articles

Impact of NCI Comprehensive Cancer Center Designation, Provider Specialization and Patient Sharing with Community Providers on Outcomes for Patients with Multiple Myeloma

Ashley T Freeman, MD, Lei Zhou, MSPH, Justin G Trogdon, PhD, Chris D Baggett, PhD, Sascha A Tuchman, MD, Thomas C. Shea, MD, William A. Wood, MD MPH

Blood (2017) 130 (Supplement 1): 529.

https://doi.org/10.1182/blood.V130.Suppl_1.529.529

Published: 2017

Journal Articles

Presence of Minimal Residual Disease at End of Induction in Acute Myeloid Leukemia Is Predictive of Poor Outcome

Blood (2017) 130 (Supplement 1): 5109.

https://doi.org/10.1182/blood.V130.Suppl_1.5109.5109

Published: 2017

Journal Articles

Initial Report of a Multi-Institution Phase I/Ib Study of Ibrutinib with Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma

Craig A. Portell, MD, Robert W Chen, MD, Nolan Wages, PhD, Jonathon B. Cohen, MD, Michael J. Weber, PhD, Gina Petroni, PhD, Brad S. Kahl, MD, Michael E Williams, MD

Blood (2016) 128 (22): 2958.

https://doi.org/10.1182/blood.V128.22.2958.2958

Published: 2016

Journal Articles

Minimal Residual Disease in Acute Myeloid Leukemia Using a Difference from Normal Approach Is Predictive of Outcome

Chinmayee Kakirde, Rohan Kodgule, Goutham Raval, Sanjay Talole, Shraddha Kadechkar, Gaurav Chatterjee, Badrinath Yajamanam, Sitaram Ghoghale, Nilesh Deshpande, Pratibha Amare Kadam, PhD, Hari Menon, MD DM., Manju Sengar, Navin Khattry, MD DM, Hasmukh Jain, Bhausaheb Bagal, MD DM, Prashant Tembhare, MD, Sumeet Gujral, MD, Nikhil Patkar, MD

Blood (2016) 128 (22): 5249.

https://doi.org/10.1182/blood.V128.22.5249.5249

Published: 2016

NARROW

Survival Patterns in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: Treatment Trajectories and Responses after the First Relapse

TEM-MM-101: A Phase I/IIa Dose Escalation Study Evaluating the Safety and Activity of Autologous CD34+ Enriched Hematopoietic Progenitor Cells Genetically Modified for Human Interferon-α2 in Multiple Myeloma Patients with Early Relapse after Intensive Front Line Therapy

Inpatient Hospitalization's Associated Cost and Mortality for Myeloma Patients Undergoing Autologous Stem Cell Transplant: A 13-Year Analysis of the National Inpatient Sample

Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming

Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information

Decreased Mortality after the First Year of Allogeneic Hematopoietic Stem Cell Transplant in Recipients of Umbilical Cord Blood Vs. Matched Related or Matched Unrelated Donors

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study

Whole Genome Sequencing Reveals Recurrent Structural Driver Events in Peripheral T-Cell Lymphomas Not Otherwise Specified

A New Cellular Immunotherapy for the Treatment of Multiple Myeloma without Development of Graft-Versus-Host Disease

Fixed Dose Carfilzomib Triplets in Lenalidomide Refractory Myeloma

CD117-Amanitin Antibody Drug Conjugates Effectively Deplete Human and Non-Human Primate HSCs: Proof of Concept As a Targeted Strategy for Conditioning Patients for Bone Marrow Transplant

Quadruple Hit Lymphoma: A Rare Entity with Dismal Prognosis

Long Term Survival Analysis of Multiple Myeloma Patients Receiving Induction Therapy+ Autologous STEM CELL Trasplantation, Comparing Velcade-Dexametasone to Alkylating Polichemotherapy As Induction Therapy

Long Acting Zoledronic Acid Treatment for Vertebral Fracture Prevention in Multipl Myeloma Patients with Osteoporosis

A Study to Identify Correlation of Hematopoietic Progenitor Cell(XN-HPC) By Sysmex Cell Counters with Final Yield of CD34 + Stem Cells

Magic-TT Mediated Hematopoietic Stem/Progenitor Cells Promote Hematopoietic Recovery after Autologous Bone Marrow Transplantation

Impact of NCI Comprehensive Cancer Center Designation, Provider Specialization and Patient Sharing with Community Providers on Outcomes for Patients with Multiple Myeloma

Presence of Minimal Residual Disease at End of Induction in Acute Myeloid Leukemia Is Predictive of Poor Outcome

Initial Report of a Multi-Institution Phase I/Ib Study of Ibrutinib with Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma

Minimal Residual Disease in Acute Myeloid Leukemia Using a Difference from Normal Approach Is Predictive of Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only